Premium
P3–258: Effects of cholinesterase inhibitors on nicotinic acetylcholine receptor levels in the rat
Author(s) -
Reid Richard,
Sabbagh Marwan N.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.1527
Subject(s) - methyllycaconitine , donepezil , chemistry , epibatidine , nicotine , pharmacology , cholinesterase , rivastigmine , nicotinic agonist , acetylcholine , nicotinic acetylcholine receptor , medicine , receptor , biochemistry , dementia , disease
Electron microscopic analysis of peripheral nerves of BACE1 deficient mice revealed pronounced hypomyelination, similar to that seen in mice haploinsufficient for NRG-1 or in conditional mutants lacking the ErbB2 receptor in Schwann cells. Thus, we show that NRG-1, a key axonal signal that is required for myelination, is a novel BACE1 substrate, and demonstrate that BACE1 is required in vivo for myelination of peripheral nerves. Therapeutic strategies focusing on treatment of Alzheimer‘s disease with BACE1 inhibitors should therefore consider downstream effects on the NRG-1/ErbB signalling system.